ATE295348T1 - Thyroid-rezeptorliganden, die von anilin ableitbar sind - Google Patents

Thyroid-rezeptorliganden, die von anilin ableitbar sind

Info

Publication number
ATE295348T1
ATE295348T1 AT01903064T AT01903064T ATE295348T1 AT E295348 T1 ATE295348 T1 AT E295348T1 AT 01903064 T AT01903064 T AT 01903064T AT 01903064 T AT01903064 T AT 01903064T AT E295348 T1 ATE295348 T1 AT E295348T1
Authority
AT
Austria
Prior art keywords
aniline
receptor ligands
thyroid receptor
ligands derived
derived
Prior art date
Application number
AT01903064T
Other languages
German (de)
English (en)
Inventor
Todd Jason Friends
Dennis E Ryono
Minsheng Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE295348T1 publication Critical patent/ATE295348T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01903064T 2000-02-17 2001-01-12 Thyroid-rezeptorliganden, die von anilin ableitbar sind ATE295348T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18322300P 2000-02-17 2000-02-17
PCT/US2001/001204 WO2001060784A1 (en) 2000-02-17 2001-01-12 Aniline-derived ligands for the thyroid receptor

Publications (1)

Publication Number Publication Date
ATE295348T1 true ATE295348T1 (de) 2005-05-15

Family

ID=22671959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01903064T ATE295348T1 (de) 2000-02-17 2001-01-12 Thyroid-rezeptorliganden, die von anilin ableitbar sind

Country Status (30)

Country Link
US (2) US6800605B1 (pl)
EP (1) EP1257526B1 (pl)
JP (1) JP4629294B2 (pl)
KR (1) KR100740383B1 (pl)
CN (1) CN1216857C (pl)
AR (1) AR031094A1 (pl)
AT (1) ATE295348T1 (pl)
AU (2) AU3092901A (pl)
BR (1) BR0108134A (pl)
CA (1) CA2400486C (pl)
CO (1) CO5271672A1 (pl)
CZ (1) CZ20022771A3 (pl)
DE (1) DE60110753T2 (pl)
DK (1) DK1257526T3 (pl)
EG (1) EG25009A (pl)
ES (1) ES2242723T3 (pl)
HK (1) HK1047925B (pl)
HU (1) HUP0301777A3 (pl)
IL (2) IL150449A0 (pl)
MX (1) MXPA02007929A (pl)
MY (1) MY124534A (pl)
NO (1) NO329639B1 (pl)
NZ (1) NZ520023A (pl)
PE (1) PE20020767A1 (pl)
PL (1) PL201790B1 (pl)
PT (1) PT1257526E (pl)
RU (1) RU2260586C2 (pl)
UY (1) UY26581A1 (pl)
WO (1) WO2001060784A1 (pl)
ZA (1) ZA200206072B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DE10131462A1 (de) * 2001-06-29 2003-01-09 Bayer Ag Phenol-Derivate
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1443919A4 (en) 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
US20040242594A1 (en) * 2001-11-17 2004-12-02 Dan Peters Prodrugs of antidepressants and their use for treating depressions
GB0208384D0 (en) * 2002-04-11 2002-05-22 Karobio Ab Novel compounds
WO2004066929A2 (en) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
US8922530B2 (en) * 2010-01-06 2014-12-30 Apple Inc. Communicating stylus
EP2609910A1 (en) 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Formulations of eprotirome
DK2695611T3 (en) * 2012-08-06 2015-01-05 Wolff August Gmbh & Co Kg Arzneimittel Dr Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX382313B (es) * 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP3894383A1 (en) * 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN115279359A (zh) 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
WO2021244582A1 (zh) 2020-06-02 2021-12-09 成都康弘药业集团股份有限公司 新型甲状腺激素β受体激动剂
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
AU2022271304A1 (en) 2021-05-06 2023-11-23 Autobahn Therapeutics, Inc. Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors
WO2023177667A1 (en) * 2022-03-16 2023-09-21 Brii Biosciences, Inc. Thyroid hormone receptor agonists
WO2025019825A2 (en) * 2023-07-20 2025-01-23 Brii Biosciences, Inc. Substituted 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phenoxy)acetamide derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1078582B (de) * 1958-10-29 1960-03-31 Hoechst Ag Verfahren zur Herstellung substituierter Thyropropionsaeuren
JPS6061747A (ja) * 1983-09-16 1985-04-09 Konishiroku Photo Ind Co Ltd 熱現像感光材料
EP0580550B1 (en) 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
WO2000051971A1 (en) 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
DE60018225T2 (de) 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
KR20020089420A (ko) * 2000-03-31 2002-11-29 화이자 프로덕츠 인코포레이티드 갑상선 수용체 리간드로서의 말로남산 및 그의 유도체
AU4884701A (en) * 2000-05-12 2001-11-20 Kissei Pharmaceutical Co. Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
WO2002094319A1 (en) * 2001-05-18 2002-11-28 Kissei Pharmaceutical Co., Ltd. Preventive or recurrence-suppressive agents for liver cancer
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor

Also Published As

Publication number Publication date
KR20020075799A (ko) 2002-10-05
PE20020767A1 (es) 2002-08-17
PT1257526E (pt) 2005-09-30
CN1216857C (zh) 2005-08-31
JP4629294B2 (ja) 2011-02-09
KR100740383B1 (ko) 2007-07-16
PL366149A1 (pl) 2005-01-24
MXPA02007929A (es) 2003-02-10
WO2001060784A1 (en) 2001-08-23
CZ20022771A3 (cs) 2003-09-17
AR031094A1 (es) 2003-09-10
MY124534A (en) 2006-06-30
ZA200206072B (en) 2004-02-11
EG25009A (en) 2011-05-16
HK1047925B (en) 2005-11-11
CO5271672A1 (es) 2003-04-30
CA2400486A1 (en) 2001-08-23
BR0108134A (pt) 2003-09-30
RU2260586C2 (ru) 2005-09-20
EP1257526B1 (en) 2005-05-11
HUP0301777A3 (en) 2010-09-28
NO20023895D0 (no) 2002-08-16
IL150449A0 (en) 2002-12-01
AU3092901A (en) 2001-08-27
NO329639B1 (no) 2010-11-22
IL150449A (en) 2008-03-20
NO20023895L (no) 2002-10-16
US6800605B1 (en) 2004-10-05
RU2002123349A (ru) 2004-01-10
ES2242723T3 (es) 2005-11-16
CA2400486C (en) 2011-01-11
US7109164B2 (en) 2006-09-19
US20050032890A1 (en) 2005-02-10
NZ520023A (en) 2004-05-28
AU2001230929B2 (en) 2004-09-23
CN1418185A (zh) 2003-05-14
HUP0301777A2 (hu) 2003-09-29
DE60110753T2 (de) 2006-02-23
DK1257526T3 (da) 2005-09-12
HK1047925A1 (en) 2003-03-14
JP2004500382A (ja) 2004-01-08
EP1257526A1 (en) 2002-11-20
PL201790B1 (pl) 2009-05-29
UY26581A1 (es) 2001-09-28
DE60110753D1 (de) 2005-06-16

Similar Documents

Publication Publication Date Title
DE60110753D1 (de) Thyroid-rezeptorliganden, die von anilin ableitbar sind
ATE297374T1 (de) Biaryletherderivate, die als inhibitoren der monoamin-wiederaufnahme nützlich sind
MXPA03007078A (es) Ligandos del receptor de canabinoide.
DK1303478T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1226188T3 (da) Fremgangsmåde til fremstilling af mannichaddukter, som indeholder polyisobutenphenol
DE69926914D1 (de) 1-heterozyklus-substituierte diarylaminen
NL1026030A1 (nl) Cannabino¤dreceptorliganden en toepassingen daarvan.
MA25403A1 (fr) Ligandes de recepteur de melanocortine
AU2003225305A8 (en) Pyridine-based thyroid receptor ligands
DE60134260D1 (de) Mettalischer katalysatorträger
MXPA03004527A (es) Compuestos antagonicos lfa-1.
DE60136596D1 (de) Fahrzeugwechselstromgenerator
DE60032885D1 (de) Fahrzeugwechselstromgenerator
IL157031A0 (en) Thyroid receptor ligands
ZA200307365B (en) Antibodies specific for CD44V6.
MA27306A1 (fr) Ligands des recepteurs de la melanocortine.
DE60141896D1 (de) N,n'-diarylguanidine als il-8-rezeptor-antagonisten
ATE433956T1 (de) Cannabinoid-rezeptorliganden
TR199800604A3 (tr) Anti-fas antikorlari.
DE50105246D1 (de) Winkel- bzw. schrägbohr-einrichtung
DE69911888D1 (de) Wäscheständer
NO20030781D0 (no) Prodrugs til NMDA-reseptor-ligander
IT1303642B1 (it) Valvola di lavaggio mobile termostaticamente.
DE60321681D1 (de) Liganden, die hemmer von den rar-rezeptoren sind
DE69936219D1 (de) Benzothienoä3,2-cüpyridine als alpha2-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1257526

Country of ref document: EP